Related Experiment Video

Updated: Aug 11, 2026

Acute Myocardial Infarction in Rats
07:45

Acute Myocardial Infarction in Rats

Published on: February 16, 2011

Inotropic agents and infarct size. Theoretical and practical considerations

M Lesch

    The American Journal of Cardiology
    |March 31, 1976
    PubMed

    Insights

    Interventions affecting myocardial oxygen balance can alter infarct size. This review discusses inotropic agents

    Area of Science:

    • Cardiology
    • Cardiovascular Physiology
    • Pharmacology

    Background:

    • Myocardial infarction (MI) size is a key determinant of patient outcomes.
    • Interventions modulating myocardial oxygen supply-demand balance show potential in limiting infarct size.

    Purpose of the Study:

    • To review the effects of inotropic agents on myocardial oxygen consumption and coronary blood flow.
    • To evaluate the potential of inotropic agents to decrease or increase infarct size in experimental models and humans.
    • To provide guidelines for using inotropic agents in acute MI patients.

    Main Methods:

    • Review of recent data on interventions affecting myocardial oxygen balance.
    • Discussion of the effects of inotropic agents on determinants of myocardial oxygen consumption and coronary blood flow.
    • Analysis of experimental animal and human data regarding infarct size modification by inotropic agents.

    Main Results:

    • Inotropic agents influence myocardial oxygen demand and supply.
    • The effect of inotropic agents on infarct size varies depending on the specific agent and clinical context.
    • Animal data provides insights but requires careful extrapolation to human clinical situations.

    Conclusions:

    • Inotropic agents can impact infarct size in acute myocardial infarction.
    • Clinical application requires careful consideration of the balance between oxygen demand and supply.
    • Guidelines are proposed for the judicious use of inotropic agents in acute MI management.

    More Related Videos

    Histological Quantification of Chronic Myocardial Infarct in Rats09:45

    Histological Quantification of Chronic Myocardial Infarct in Rats

    Published on: December 11, 2016

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

    Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

    Published on: April 17, 2021

    Related Concept Videos

    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    Regulation of Stroke Volume01:27

    Regulation of Stroke Volume

    The regulation of stroke volume, which is the amount of blood the heart pumps out during each heartbeat, is critical for maintaining a healthy circulatory system. Stroke volume is influenced by three main factors: preload, contractility, and afterload.
    Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
    Ischemic Stroke ll: Pathophysiology01:15

    Ischemic Stroke ll: Pathophysiology

    An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...